ScripsAmerica, a supplier of prescription and OTC drugs, has entered into talks with Forbes Investment Ltd. to market, supply, distribute and adapt ScripsAmerica’s RapiMed® products throughout China.
Jun Liang, manager of Forbes Ltd. in Shenzhen, China, is making arrangements for ScripsAmerica to meet with the investment group’s pharmacy and hospital buying networks as part of an upcoming sales agreement that would introduce RapiMed into the Chinese OTC drug market.
“ScripsAmerica’s RapiMed Products are uniquely formulated to meet China’s market needs. It allows the country’s pharmaceutical companies, hospitals, nursing facilities, research institutes and the military to adapt RapiMed to fit their situations,” Lang stated in the press release. “With children making up over 17 percent of China’s nearly 1.5 billion population, RapiMed for children will be a target market of the company’s initial sales penetration. With the tablets ease to administer without the need for water, simple packaging for retail sales, precise dosing, and bulk distribution, it has spurred the interest beyond the children’s market. Forbes believes that the company’s product technology can be adapted for medications ranging from pain to diabetes.”
Liang also noted two additional markets that hold“enormous sales potential” for ScripsAmerica’s technology: retailing and distributing erectile dysfunction products and sales to the military.
“One in three Chinese men displays some symptoms of ED. This translates into almost one hundred million men and the perfect opportunity for the ‘Quickmelt’ technology of RapiMed to gain acceptance throughout this vast country …. We [also] believe that the technology of RapiMed has great potential for deployed personnel in normal and difficult field situations,” said Liang.
Formal sales and marketing negotiations will take place later this month, followed by technology protection agreements – Forbes said that it expects the formal exchange of agreements to be finalized before the end of September.
For more information visit http://www.scripsamerica.com
Let us hear your thoughts below: